2	Wastewater sequencing from a rural community enables identification of
3	widespread adaptive mutations in a SARS-CoV-2 Alpha variant
4	Michael J. Conway ^{1,5*} , Michael P. Novay ¹ , Carson M. Pusch ¹ , Avery S. Ward ¹ , Jackson
5	D. Abel ¹ , Maggie R. Williams ^{4,5} , Rebecca L. Uzarski ³ , and Elizabeth W. Alm ^{2,5}
6	¹ Foundational Sciences, Central Michigan University
7	College of Medicine, Mt. Pleasant, MI, USA
8 9	² Department of Biology, Central Michigan University, Mt. Pleasant, MI, USA
10	³ Department of Biology and Herbert H. and Grace A. Dow College of Health
11	Professions, Central Michigan University, Mt. Pleasant MI, USA
12 13	⁴ School of Engineering & Technology, Central Michigan University, Mt. Pleasant, MI, USA
14 15	⁵ Institute for Great Lakes Research, Central Michigan University, Mt. Pleasant, MI, USA
16 17	
18	# Address correspondence to: Foundational Sciences, Central Michigan University
19	College of Medicine, Mount Pleasant, MI, 48859
20	E-mail: michael.conway@cmich.edu. Phone: (989) 774-3930, Fax: (989) 774-3462
21 22 23 24	Short title: Complete Alpha Reconstruction
25	
26	

27 Abstract

28

Background: Central Michigan University (CMU) participated in a state-wide wastewater monitoring program starting in 2021. One rural site consistently produced higher concentrations of SARS-CoV-2 genome copies. Samples from this site were sequenced retrospectively and exclusively contained a derivative of Alpha variant lineage B.1.1.7 that shed from the same site for 20-28 months.

34 **Results:** Complete reconstruction of each SARS-CoV-2 open reading frame (ORF) and 35 alignment to an early B.1.1.7 clinical isolate identified novel mutations that were selected 36 in non-structural (nsp1, nsp2, nsp3, nsp4, nsp5/3CLpro, nsp6, RdRp, nsp15, nsp16, 37 ORF3a, ORF6, ORF7a, and ORF7b) and structural genes (Spike, M, and N). These were 38 rare mutations that have not accumulated in clinical samples worldwide. Mutational 39 analysis revealed divergence from the reference Alpha variant lineage sequence over 40 time. We present each of the mutations on available structural models and discuss the 41 potential role of these mutations during a chronic infection.

42 **Conclusions:** This study further supports that small wastewater treatment plants can 43 enhance resolution of rare events and facilitate reconstruction of viral genomes due to the 44 relative lack of contaminating sequences and identifies mutations that may be associated 45 with chronic infections.

- 46
- 47
- 48
- 49

- 50 **Declarations**
- 51 -Ethics approval and consent to participate
- 52 Not applicable
- 53 -Consent for publication*
- 54 Not applicable
- 55 -Availability of data and materials
- 56 FASTQ files for each sample are available in the NCBI SRA database (Submission
- 57 ID: SUB13897431; BioProject ID: PRJNA1027333).
- 58 -Competing interests
- 59 The authors have no competing interests.
- 60 -Funding
- 61 Michigan Department of Health and Human Services (MDHHS)
- 62 -Authors' contributions
- 63 MJC wrote the manuscript and directed the wastewater monitoring activities, MPN
- 64 reconstructed ORFs, CMP analyzed FASTQ data and developed the heatmap, ASW
- 65 and JDA performed all wastewater monitoring activities including submission of
- 66 samples for NGS, MRW supported data analysis and submission to the health
- 67 department and manuscript revision, RLU served as a liaison between wastewater
- 68 treatment plants and student research assistants, and EWA assisted in data analysis
- 69 and manuscript revision.
- 70 -Acknowledgements
- 71 We thank MDHHS and MiNET for supporting wastewater collection, 72 processing, and data analysis. We also thank the WWTP staff who provided

samples every week during a pandemic. We thank CMU undergraduate assistants
Justus Holben, Gabrielle Reau, Jessica Broach, Hamzah Khan, Jayde-Ann Taylor,
Ashley Bergmooser, Kaitlyn Perry, Emily Rosema, Alexis Bruce, and Lauren
Revord for their support. This is contribution number XXX of the Central
Michigan University Institute for Great Lakes Research.

78

79 **1. Introduction**

Wastewater monitoring has become a firmly established public health tool since the COVID-19 pandemic. Wastewater monitoring programs have helped identify potential outbreaks within communities and individual buildings, they can track variants of concern, and they are being leveraged for new emerging infectious diseases (1-12). The goal of wastewater monitoring is to provide complementary data to public health agencies so that they can make informed decisions to mitigate infectious disease transmission.

87

The State of Michigan Department of Health and Human Services (MDHHS) initiated a wastewater monitoring program in 2021. The program included partnerships between academic laboratories and regional public health departments that spanned large and small metropolitan areas and rural areas in both lower and upper peninsulas. Central Michigan University (CMU) formed a partnership with the Central Michigan District Health Department (CMDHD). This partnership provided an opportunity to look at the dynamics of SARS-CoV-2 at a regional public university and in the surrounding small

95 metropolitan and rural communities (13). We identified ten on-campus sewer sites and
96 nine off-campus wastewater treatment plants (WWTPs) to sample on a weekly basis.

97

98 Sampling began in July 2021, which was at least seven months after emergence of 99 the Alpha variant (B.1.1.7) in Michigan. The Alpha variant first appeared in North 100 America in late November 2020 and became the predominant SARS-CoV-2 variant by 101 the end of March 2021 (14). It became clear that our smallest WWTP (estimated 102 population served: 851) consistently produced higher concentrations of SARS-CoV-2 103 genome copies. Samples taken from this site from 2021-2023 were retrospectively 104 sequenced and many contained sequences that corresponded to an Alpha variant lineage 105 B.1.1.7. We reconstructed the Spike gene and identified 37 mutations that accumulated in 106 the RBD and NTD (15). Here, we use the same set of data to provide a complete 107 reconstruction of each SARS-CoV-2 open reading frame (ORF). Alignment of each ORF 108 to an early B.1.1.7 clinical isolate identified novel mutations that were selected in non-109 structural (nsp1, nsp2, nsp3, nsp4, nsp5/3CLpro, nsp6, RdRp, nsp15, nsp16, ORF3a, 110 ORF6, ORF7a, and ORF7b) and structural genes (Spike, M, and N). Each of these 111 mutations were present in less than 2% of clinical samples present in GenBank and the 112 sequence read archive (SRA) from Dec 2023 to Jun 2024. These were rare mutations, yet 113 three were previously associated with immunodeficiency, adaptation to remdesivir, and 114 reinfection of a hospital worker (16-20). Temporal mutational analysis revealed 115 divergence from the reference Alpha variant lineage sequence over time. Each mutation 116 was mapped onto available structural models, and we discuss the potential significance of 117 these changes during a chronic SARS-CoV-2 infection.

119	This manuscript provides further support that wastewater monitoring in small
120	metropolitan and rural communities is an opportunity to identify novel variants and
121	reconstruct whole genomes due to lower contamination with unrelated sequences. It is
122	important to note that the reconstruction strategy that was used will incorporate
123	contaminating variant sequences if they are present. These data also support that humans
124	can chronically shed SARS-CoV-2 for close to two years. Considering the low
125	prevalence of these mutations in clinical samples, chronic shedding of SARS-CoV-2 is
126	likely a rare event that leads to accumulation of adaptive mutations. Identifying mutations
127	associated with chronic infection may be useful to diagnose individuals who have
128	persistent disease and to assist in the selection of appropriate treatment.

2. Materials and methods

2.1. Selection of sample sites

Central Michigan University (CMU) is a public research university in the City of Mt. Pleasant, Isabella County, Michigan, with an average population during the 2021-2022 academic year of 13,684 students and staff. Ten sample sites were selected on campus that collected wastewater downstream from most campus buildings, including residential halls, apartments, and academic/administrative buildings. The waste stream at these sites includes a mixture of wastewater from CMU and upstream residential areas in the City of Mt. Pleasant. Nine off-campus sites throughout the jurisdictions of the Central Michigan District Health Department (CMDHD) and Mid-Michigan District Health

141 Department (MMDHD) were selected (13), which included the City of Mt. Pleasant, 142 Union Township, City of Alma, City of Clare, City of Evart, three Houghton Lake 143 townships, and Village of Marion wastewater treatment plants (WWTPs). These locations 144 represent various land uses and population densities including urban, rural, and suburban 145 areas, providing a large footprint of SARS CoV-2 virus shedding in Central Michigan.

146

147 **2.2. Wastewater collection**

Since July 2021, wastewater samples (500–1000 mL) were collected once each week on either Monday or Tuesday from ten sanitary sewer sites and nine WWTP influent streams (after grit removal). Sanitary sewer grab samples consisted of wastewater flowing from university dormitories and buildings and the surrounding community. Influent to WWTPs were collected as grab samples or 24-hour composite samples. Samples were held at 4°C no more than 48 hours before analysis (13).

154

155 **2.3. Virus concentration and RNA extraction**

156 The protocol described by Flood et al. 2021 and adopted by the Michigan 157 wastewater monitoring network was used to concentrate virus from samples and extract 158 viral RNA (13, 53). Briefly, 100 mL wastewater or water as a negative control was mixed 159 with 8% (w/v) molecular biology grade PEG 8000 (Promega Corporation, Madison WI) 160 and 0.2 M NaCl (w/v). The sample was mixed slowly on a magnetic stirrer at 4 °C for 2-161 16 hours. Following overnight incubation, samples were centrifuged at $4,700 \times g$ for 45 162 min at 4 °C. The supernatant was then removed, and the pellet was resuspended in the 163 remaining liquid, which ranged from 1-3 mL. All sample concentrates were aliquoted and

164 stored at -80 °C until further processing. Viral RNA was extracted from concentrated 165 wastewater using the Qiagen QIAmp Viral RNA Minikit according to the manufacturer's 166 protocol with previously published modifications (Qiagen, Germany) (53). In this study, 167 a total of 200 µl of concentrate was used for RNA extraction resulting in a final elution 168 volume of 80 µl. Extracted RNA was stored at -80 °C until analysis. A wastewater 169 negative extraction control was included. To derive recovery efficiencies for each sample site, samples were inoculated with 10^6 gene copies (GC)/mL Phi6 bacteriophage (Phi6) 170 171 prior to the addition of PEG and NaCl. Wastewater samples were mixed, and a 1 mL 172 sample was reserved and stored at -80 °C. RNA was extracted as stated above.

173

174 **2.4. Detection and quantification of SARS-CoV-2**

175 A one-step RT-ddPCR approach was used to determine the copy number/20 µL of 176 SARS-CoV-2, and data were converted to copy number/100 mL wastewater for N1 and 177 N2 targets using the method published by Flood et al., 2001 (53). All the primers and 178 probes used in this study were published previously (13). Droplet digital PCR was 179 performed using Bio-Rad's 1-Step RT-ddPCR Advanced kit with a QX200 ddPCR 180 system (Bio-Rad, CA, USA). Each reaction contained a final concentration of $1 \square \times \square$ Supermix (Bio-Rad, CA, USA), 20 U μ L⁻¹ reverse transcriptase (RT) (Bio-Rad, 181 CA, USA), 15 mM DTT, 900 nmol l⁻¹ of each primer, 250 nmol l⁻¹ of each probe, 1 µL of 182 183 molecular grade RNAse-free water, and 5.5 µL of template RNA for a final reaction 184 volume of 22 µL (13, 53-55). RT was omitted for DNA targets. Droplet generation was 185 performed by microfluidic mixing of 20 µL of each reaction mixture with 70 µL of 186 droplet generation oil in a droplet generator (Bio-Rad, CA, USA) resulting in a final

187 volume of 40 µL of reaction mixture-oil emulsions containing up to 20,000 droplets with 188 a minimum droplet count of $\Box > \Box 9000$. The resulting droplets were then transferred to a 189 96-well PCR plate that was heat-sealed with foil and placed into a C1000 96-deep-well 190 thermocycler (Bio-Rad, CA, USA) for PCR amplification using the following 191 parameters: 25 °C for 3 min, 50 °C for 1 h, 95 °C for 10 min, followed by 40 cycles of 95 192 °C for 30 s and 60 °C for 1 min with ramp rate of 2 °C/s 1 followed by a final cycle of 98 193 °C for 10 min. Following PCR thermocycling, each 96-well plate was transferred to a 194 QX200 Droplet Reader (Bio-Rad, CA, USA) for the concentration determination through 195 the detection of positive droplets containing each gene target by spectrophotometric 196 detection of the fluorescent probe signal. All analyses were run in triplicate for each 197 marker. To derive recovery efficiencies for each sample site, Phi6-spiked pre- and post-PEG concentration RNA samples were used to quantify Phi6 copy number using the 198 199 previously published primers and probes (13). The degree of PCR inhibition was also quantified in each sample by spiking 10 µL of 10⁵ GC/ml Phi6 in a sample's Buffer 200 201 AVL, including positive controls that lacked wastewater.

202

203 **2.5. Data analysis**

All SARS-CoV-2 gene data were converted from GC per 20 μ L reaction to GC per 100 mL wastewater sample before analysis (13, 53). Non-detects (ND) were assigned their individual sample's limit of detection for the purposes of data reporting, although any weekly on-campus or off-campus samples whose values matched the theoretical limit of detection were removed prior to statistical analysis. The limit of detection was calculated for each individual sample based on both the molecular assays' theoretical

210	detection limits (i.e., 3 positive droplets for RT-ddPCR; the lowest standard curve							
211	concentration for RT-qPCR) and the concentration factor of each processing method							
212	examined. All wastewater data were reported to MDHHS and uploaded to the Michigan							
213	COVID-19 Sentinel Wastewater Epidemiological Evaluation Project (SWEEP)							
214	dashboard (https://www.michigan.gov/coronavirus/stats/wastewater-							
215	surveillance/dashboard/sentinel-wastewater-epidemiology-evaluation-project-sweep).							
216								
217	2.6. Sequencing							
218	RNA was shipped to GT Molecular (Fort Collins, CO) on dry ice. Library							
219	preparation was done using GT Molecular's proprietary method, which utilized ARTIC							

220 4.1 primers for SARS-CoV-2 amplicon generation (https://artic.network/ncov-2019).

Amplicons were pooled and sequenced on a Miseq using 2x150bp reads. FASTQ files were analyzed using GT Molecular's bioinformatics pipeline, and variant-calling was performed using a modified and proprietary version of Freyja (56). FASTQ files for each sample listed are available in the NCBI SRA database (Submission ID: SUB13897431; BioProject ID: PRJNA1027333) (15).

226

227 **2.7.** Complete reconstruction and identification of novel mutations

FASTQ files from 10-26-21 (SAMN37791375), 11-9-21 (SAMN37791376), 9-12-22 (SAMN37791379), 3-13-23 (SAMN37791380), 4-24-23 (SAMN37791382), and 5-1-23 (SAMN37791383) contained reads that spanned each SARS-CoV-2 open reading frame (ORF), they lacked contamination with other variants of concern based on variant calling, and they had high relative abundance of the Alpha

233 variant lineage B.1.1.7 derivative (Table 1) (15). This allowed for reconstruction of 234 consensus genes for each of the above wastewater samples. Specifically, we uploaded 235 FASTA-formatted .txt files into Galaxy (https://usegalaxy.org/) that represented each 236 reference gene. Reference genes were constructed from an early consensus Alpha variant 237 lineage B.1.1.7 Michigan clinical isolate submitted on 1-26-21 (GenBank: MW525061.1; 238 Accession: MW525061). We then uploaded each of the paired-end FASTQ files for each 239 wastewater sample. The Bowtie2 program was used to map reads against each reference 240 sequence, creating individual .bam files per sample. The default setting was used for 241 analysis. The Convert Bam program was then used to convert .bam files to FASTA 242 multiple sequence alignments. Multiple sequence alignment files were uploaded to 243 MEGA (https://www.megasoftware.net/) and converted to amino acid sequence. The 244 consensus amino acid sequence from each of these samples was manually reconstructed 245 and then aligned with the reference gene. Mutations that were present in wastewater 246 samples but not the reference clinical sample were characterized as novel mutations. The 247 total number of reads that aligned to each reference gene were determined in MEGA and 248 FastQC was used to quantify read length and the number of poor-quality sequences 249 (Supplementary Table 1). At least 3 reads were present for each amino acid.

250

251 2.8. Novel mutation hotspot analyses

We identified novel mutations as described above. We then tracked the percent prevalence of novel mutations in wastewater samples that were positive for the Alpha variant lineage. Specifically, we uploaded FASTA-formatted .txt files into Galaxy (https://usegalaxy.org/) that represented the SARS-CoV-2 reference genes. We then

256 uploaded each of the paired-end FASTO files for each wastewater sample. The Bowtie2 257 program was used to map reads against the reference sequence. The default setting was 258 used for analysis. The Convert Bam program was then used to convert .bam files to 259 FASTA multiple sequence alignments. Multiple sequence alignment files were uploaded 260 to MEGA (https://www.megasoftware.net/) and converted to amino acid sequence for 261 open-reading frame analysis. Novel mutations were identified manually, and the column 262 of reads were copied and pasted into Excel. The column was selected, and the Analyze 263 Data tool was selected to calculate the percent prevalence of the novel mutations. This 264 was repeated for each novel mutation across all samples positive for Alpha variant 265 lineage and the percent prevalence data was represented in a heatmap. Novel mutations 266 were mapped onto 2-D representations of proteins and the 3-D protein structures when 267 available using UCSF Chimera (57).

268

269 **3. Results**

270 **3.1 Chronic shedding of an Alpha variant lineage at a rural WWTP.**

271 Wastewater samples were collected between July 2021 and June 2023 and SARS-272 CoV-2 genome copies per 100 mL wastewater were determined each week and reported 273 to MDHHS (13, 15). One site was notable for higher peaks of virus shedding, which 274 culminated in a peak that was 4 logs higher than the mean for all sites, although high 275 peaks of activity were observed since 9-21-21 (15). In order to identify the SARS-CoV-2 276 variant responsible for this activity, RNA extracted from stored wastewater concentrates 277 was shipped to GT Molecular (Fort Collins, CO) and a next generation sequencing (NGS) 278 and variant calling pipeline was employed. RNA from the site of interest and neighboring

279 sites were analyzed as a control. The site of interest contained high relative abundance of 280 Delta variant lineage AY.25.1 at the first time point tested (i.e., 9-21-21) (15). This 281 corresponded to the beginning of the Delta variant wave in Central Michigan (13). The 282 site of interest began shedding the Alpha variant lineage during the next two time points 283 tested (10-26-21 and 11-9-21) (15). This was preceded by sequencing data from clinical 284 samples, which revealed 16 Alpha variant lineage Q.3 isolates collected from 2-18-21 to 285 7-9-21 (15). The site of interest had high relative abundance of Omicron variant lineages 286 during the next two time points tested (i.e., 3-14-22 and 4-25-22) (15). This corresponded 287 to the end of the first Omicron wave in Central Michigan (13). The Alpha variant lineage 288 became the dominant isolate in all remaining wastewater samples from the site of interest 289 in all 2022 and 2023 samples tested, with relative abundance ranging from 47.1-98.0% 290 (15). Specifically, for the samples analyzed in the current manuscript (i.e., 10-26-2021, 291 11-9-2021, 9-12-2022, 3-13-23, 4-24-23, and 5-1-23), the alpha variant represented 94.2-292 98% of amplicons. Based on this information, it was possible to reconstruct alpha variant 293 genomes without significant contamination with other variants (Supplementary Figure 1). 294 Other sites contained Omicron variant lineages BG.5, XBB.1.5, XBB.1.5.23, XBB.1.28, 295 XBB.1.5.1, XBB.1.5.17, XBB.1.5.49, and Delta variant lineage DT.2 at varying relative 296 abundance during the same sampling period (15).

297

3.2. Accumulation of novel mutations.

We reasoned that chronic shedding of SARS-CoV-2 would lead to accumulation of novel mutations that do not align with sequences identified in most clinical and wastewater samples, which mostly result from acute infection. This hypothesis was

302 supported by our previous analysis of Spike, which identified 37 novel mutations that 303 accumulated during this time frame (15). Alignment of reconstructed consensus genes 304 with a reference Alpha variant lineage clinical sequence revealed that non-Spike proteins 305 had 35 novel mutations in the 5-1-2023 sample including mutations in nsp1 (1), nsp2 (1), 306 nsp3 (8), nsp4 (4), nsp5/3CLpro (2), nsp6 (2), RdRp (2), nsp15 (2), nsp16 (1), ORF3a 307 (4), M (2), ORF6 (1), ORF7a (1), ORF7b (1), and N (3) (Fig. 1). Each mutation was 308 analyzed using the NCBI Virus SARS-CoV-2 Variant Overview "Search GenBank + 309 SRA Data by Mutation" tool. This analysis identified the total records for each mutation 310 in GenBank and SRA databases during the time frame of Dec 2023 to Jun 2024. 311 Importantly, this time frame was 7 to 13 months after the last wastewater sample was 312 acquired. Very few records were identified for each of these mutations and some 313 mutations lacked records altogether (Table 2). We expanded the mutational analysis by 314 quantifying the percent prevalence of each of the 35 novel mutations identified in the 5-1-315 2023 sample across all wastewater samples that were positive for the Alpha variant 316 lineage. A heatmap showed that these mutations accumulated and became dominant 317 within the population over time, while also retaining diversity at each position (Fig. 2).

318

319 3.3. Nsp1

One novel mutation accumulated in nsp1: S17I. S17I resides in the N-terminal domain
(NTD) (Figure 3A). It was found in 1 online record (Table 2). The impact of this
mutation on protein function and immune evasion is unknown.

323

324 **3.4. Nsp2**

One novel mutation accumulated in nsp2: G445C (G265C). ORF1ab mutations outside of parentheses were determined from the first amino acid in nsp1. ORF1ab mutations inside of parentheses were determined from the first amino acid of each protein. Both variations were searched in the literature. G445C (G265C) was reported in India and found in a total of 26 online records (Table 2) (21). The impact of this mutation on protein function and immune evasion is unknown.

331

332 **3.5.** Nsp3

Eight novel mutations accumulated in nsp3: S944L (S126L), D1184E (D366E), A1306S (A488S), H1545Y (H727Y), K1795Q (K977Q), R2115I (R1297I), H2520N (H1702N), and S2661F (S1843F). S944L (S126L) resides in the hypervariable region (HVR), D1184E (D366E) resides in macrodomain II (Mac2), A1306S (A488S) resides in macrodomain III (Mac3), H1545Y (H727Y) resides in the ubiquitin-like domain 2 (Ubl2), K1795Q (K977Q) resides in the PL2^{pro} domain, R2115I (R1297I) resides within

the betacoronavirus-specific marker (β SM), and H2520N (H1702N) and S2661F

340 (S1843F) reside in the Y1 and CoV-Y domains (Figure 3C). S944L (S126L), A1306S 341 (A488S), and S2661F (S1843F) were reported in Asian isolates and found in a total of 342 208, 0, and 42 online records, respectively (Table 2) (22-25). H1545Y (H727Y) was 343 reported in Italy and found in a total of 5 online records (Table 2) (26). K1795Q (K977Q) 344 was reported in Brazil, was present at a higher frequency in immunodeficient patients, 345 and found in a total of 13 online records (Table 2) (27, 28). R2115I (R1297I) was 346 reported in Moldova and found in a total of 14 online records (29). D1184E (D366E) and 347 H2520N (H1702N) have not been previously reported and were found in a total of 14 and

348 0 online records, respectively. The impact of these mutations on nsp3 protein function349 and immune evasion is unknown.

350

351 3.6. Nsp4

352 Four novel mutations accumulated in nsp4: M2796I (M33I), V2943F (V180F), I2961F 353 (I198F), and D2980G (D217G). M2796I (M33I) resides in a transmembrane domain 354 (TD), and V2943F (V180F), I2961F (I198F), and D2980G (D217G) reside in the luminal 355 domain (LD) (Figure 3D). M2796I (M33I) was reported in the Middle East and 356 computational analysis suggested that the mutation causes secondary structure changes 357 converting an alpha helix to a beta sheet, which may impact interaction between nsp3 and 358 nsp4 (30, 31). D2980G (D217G) and M2796I (M33I) were reported in Asian isolates and 359 were found in a total of 21 and 72 online records, respectively (32, 33). V2943F (V180F) 360 and I2961F (I198F) have not been previously reported and were found in a total of 3 and 361 0 online records, respectively. The impact of these mutations on protein function and 362 immune evasion are unknown.

363

364 3.7. Nsp5/3CLpro

Two novel mutations accumulated in nsp5: R3353K (R90K) and K3499R (K236R). R3353K (R90K) resides in domain 1 (D1) and K3499R (K236R) resides in D3 (Figure 3E). R3353K (R90K) was not previously reported and was found in 0 online records (Table 2). K3499R (K236R) was reported in Indian isolates and was found in a total of 5 online records (Table 2) (32). The impact of these mutations on protein function and immune evasion are unknown.

371

372 **3.8. Nsp6**

373	Two novel mutations accumulated in nsp6: L3606F (L37F) and F3750V (F184V).
374	L3606F (L37F) resides in a transmembrane domain (TD) and F3750V (F184V) resides in
375	a luminal domain (LD) (Figure 3F). L3606F (L37F) was reported in Asian isolates and
376	was found in a total of 1,698 (2%) online records (Table 2) (34). Previous research found
377	that L3606F (L37F) reduced nsp6's interaction with ATP6AP1. This allowed for
378	lysosomal acidification to proceed normally, which prevented activation of the NLRP3
379	inflammasome pathway. The investigators noted that this mutation reduced SARS-CoV-2
380	fitness, and that this may be why the mutation is not present in circulating variants of
381	concern (35, 36). F3750V (F184V) was reported in a basic science study as an adaptive
382	mutation that arose in ferrets and <i>in vitro</i> during treatment with remdesivir (16, 17). This
383	mutation was not reported in clinical sequences but was present in a total of 8 online
384	records (Table 2).

385

386 3.9. RdRp

Two novel mutations accumulated in RdRp: S4618N (S229N) and T5301N (T912N). S4618N (S229N) resides in the NTD and T5301N (T912N) resides in the thumb domain (TD) (Figure 3G). S4618N (S229N) was not previously reported and was present in a total of 42 online records (Table 2). T5301N (T912N) was reported in Italy and was present in a total of 0 online records (Table 2) (37). The impact of these mutations on protein function and immune evasion are unknown.

394	3.10.	Nsp1:	5
-----	-------	-------	---

Two novel mutations accumulated in nsp15: E6709K (E260K) and F6712L (F263L).
Both E6709K (E260K) and F6712L (F263L) reside in the nuclease EndoU domain
(Figure 3H). E6709K (E260K) was reported in Italy and was present in a total of 4 online
records (Table 2). This mutation was associated with an increased frequency of mortality
(38). F6712L (F263L) was not previously reported and was present in a total of 14 online
records (Table 2). The impact of these mutations on protein function and immune evasion
are unknown.

403 **3.11. Nsp16**

404 One novel mutation accumulated in nsp16: R7011N (R216N). R7011N (R216N) was 405 reported in Brazil and was present in a total of 0 online records (Table 2). This mutation 406 was associated with reinfection of a healthcare worker (19). The impact of this mutation 407 on protein function and immune evasion is unknown.

408

409 **3.12. ORF3a**

410 Four novel mutations accumulated in ORF3a: I35K, E102D, G172R, and M260K. I35K

411 resides in the N-terminal domain (NTD), E102D resides in the transmembrane domain

412 (TD), and both G172R and M260K reside in the C-terminal domain (CTD) (Figure 4A).

413 I35K and E102D have not been previously reported. G172R and M260K were previously

414 reported in variants of concern (39-42). The impact of these mutations on ORF3a protein

415 function and immune evasion is unknown.

417	3.13. M
418	Two novel mutations accumulated in M: D3N and Q19H. Both mutations reside in the N-

419 terminal domain (NTD), which are surface exposed (Figure 4B). D3N was previously

420 identified in BA.5 strains and may result in N-myristoylation possibly impacting

421 membrane integrity, post-translational modification, and immune evasion (43, 44). Q19H

422 has not been previously reported but based on its location it may have similar functional

423 consequences as D3N.

424

```
425 3.14. ORF6
```

One novel mutation accumulated in ORF6: D61E. This is the last residue in the open
reading frame. D61E has not been previously reported. The impact of this mutation on
ORF6 protein function and immune evasion is unknown.

429

430 **3.15. ORF7**a

One novel mutation accumulated in ORF7a: T120I. This is the second to last C-terminal
residue and resides in the endoplasmic reticulum retention sequence (Figure 4D). T120I
has been previously identified in variants of concern (45). The impact of this mutation on
ORF7a protein function and immune evasion is unknown.

435

436 **3.16. ORF7b**

437 One novel mutation accumulated in ORF7b: A43V. This is the last residue in the C-

438 terminal domain (Figure 4E). A43V has not been previously reported. The impact of this

439 mutation on ORF7b protein function and immune evasion is unknown.

440

441 **3.17.** N

442 Three novel mutations accumulated in the N gene: N8D, S37P, and F235S. N8D resides

- 443 in the N-terminal domain (NTD) and both S37P and F235S reside in the linker sequence
- 444 between the known functional domains (Figure 4F). N8D was previously identified in
- 445 B.1.1.7 strains (46, 47). S37P was previously identified in SARS-CoV-2 isolates (48, 49).
- F235S has not been previously reported. The impact of these mutations on N proteinfunction and immune evasion is unknown.
- 448

449 **4. Discussion**

450 Retrospective analysis of wastewater data revealed that one rural site produced 451 consistently higher concentrations of SARS-CoV-2 copy numbers. NGS sequencing 452 revealed that this site began shedding an Alpha variant lineage by October 2021 and that 453 this continued to at least May 2023. Clinical sequence data revealed that Alpha variant 454 lineage Q.3/Q.4 was present in Michigan between February to July 2021. This preceded 455 the start of wastewater surveillance in central Michigan and our first detection of the 456 Alpha variant lineage in wastewater by 3-8 months. It is unclear how many individuals 457 were originally infected with this lineage at the site of interest, and it is unclear how 458 many individuals continued to shed the virus into the sewer shed. However, due to the 459 small population served at this rural WWTP, our October 2021 Alpha variant lineage 460 reconstruction likely represents a chronic infection that lasted for 2-7 months. At this 461 stage of the chronic infection, the Alpha variant lineage already accumulated 9 novel

462 mutations in the Spike gene and 10 novel mutations spread across nsp1, nsp3, nsp5, nsp6,
463 nsp15, nsp16, and N (15).

464

465 Eighteen months later, the Alpha variant lineage shed from this site had 72 novel 466 non-structural (nsp1, nsp2, nsp3, nsp4, nsp5/3CLpro, nsp6, RdRp, nsp15, nsp16, ORF3a, 467 ORF6, ORF7a, and ORF7b) and structural (Spike, M, and N) mutations (15). Spike 468 mutations present in these wastewater samples have been described previously. Many of 469 the Spike mutations were associated with experimental evidence suggesting they 470 promoted immune evasion, and three mutations were previously found in 471 immunocompromised patients (15). Similarly, nsp3 K1795Q (K977Q) was present at a 472 higher frequency in immunodeficient patients, nsp6 F3750V (F184V) was an adaptive 473 mutation that accumulated in the presence of remdesivir *in vitro* and *in vivo*, and nsp16 474 R7011N (R216N) was present in a reinfected healthcare worker (16, 17, 19, 28). 475 Considering that 8% of the novel mutations in Spike and non-Spike genes were 476 associated with known persistent infections, we can assume that many of the identified 477 mutations are selected during chronic infection.

478

Without experimental evidence, it is impossible to know the precise role of each mutation during chronic infection, although we can infer based on known structural and functional information for each protein, in addition to serological data in the human host. For instance, the two mutations present in M protein (D3N and Q19H) reside in the Nterminal domain (NTD) and are surface exposed (50, 51). Previous research has identified D3N in BA.5 strains and investigators suggested that the mutation may result

in N-myristoylation possibly impacting membrane integrity, post-translational modification, and immune evasion (43, 44). Similar to Spike, antibodies directed to M are generated during infection, persist for at least a year after infection, and generate a similar level of reactivity as immunodominant linear epitopes (50-52). It's possible that during a chronic infection SARS-CoV-2 optimizes Spike and M to evade adaptive immunity.

491

492 These data provide evidence that, while rare, an individual can be chronically 493 infected with SARS-CoV-2 over many months and possibly a few years. It is possible 494 that multiple individuals contributed to the persistence of this variant of concern. During 495 this time, SARS-CoV-2 can accumulate many mutations in Spike and non-Spike genes. 496 Some of these mutations have been found in persistent infections. Further research is 497 needed to determine which of these mutations are predictive of chronic infection and if 498 they can be used as a biomarker in individuals with persistent disease and leveraged to 499 tailor selection or development of pharmaceutical therapies. This study also shows that 500 small WWTPs can enhance the resolution of rare biological events and allow for total 501 reconstruction of viral genomes and their corresponding proteins.

502

503 **Figure legends**

504

505 Figure 1. SARS-CoV-2 genome map with novel mutations identified as red dashes 506 under each open reading frame (ORF): nsp1 (1), nsp2 (1), nsp3 (8), nsp4 (4),

507	nsn5/3CLpro	(2), nsp	6 (2)	RdRr	n (2), ns	n15 (2).	nsp16(1)	. S (37).	. ORF3a ((4).	М (2).
507	Insperse Lipit	(2), 1 0 P	• (=)) INGIN				(J)	, om ou ((

- 508 **ORF6** (1), **ORF7a** (1), **ORF7b** (1), and N (3).
- 509

Figure 2. Heatmap showing the percent prevalence of novel non-Spike mutations in each wastewater sample that was positive for the Alpha variant lineage. ORF1ab mutations outside of parentheses were determined from the first amino acid in nsp1. ORF1ab mutations inside of parentheses were determined from the first amino acid of each protein.

515

516 Figure 3. Novel mutations present in ORF1ab genes were mapped onto 2-D and 3-D 517 protein models: (A) nsp1, (B) nsp2, (C) nsp3, (D) nsp4, (E) nsp5/3CLpro, (F) nsp6, 518 (G) RdRp, (H) nsp15, and (I) nsp16. Structures were rendered using UCSF Chimera 519 and RCSB PDB numbers were provided (58). Individual protein domains were 520 indicated in blue and multimers/other molecules were indicated as gray. Mutations 521 were highlighted and noted in red.

522

Figure 4. Novel mutations present in ORF genes were mapped onto 2-D and 3-D protein models. (A) ORF3a, (B) M, (C) ORF6, (D) ORF7a, (E) ORF7b, and (F) N. Structures were rendered using UCSF Chimera and RCSB PDB numbers were provided (58). Individual protein domains were indicated in blue and multimers/other molecules were indicated as gray. Mutations were highlighted and noted in red.

529

530 Supplementary Figure 1. Reconstructed ORFs in FASTA format

531 Supplementary Table 1. Total RNA-Seq reads present for each SARS-CoV-2 ORF

532

533 **References**

Anderson-Coughlin BL, Shearer AEH, Omar AN, Litt PK, Bernberg E, Murphy
 M, et al. Coordination of SARS-CoV-2 wastewater and clinical testing of university
 students demonstrates the importance of sampling duration and collection time. Sci Total
 Environ. 2022;830:154619.

538 2. Betancourt WQ, Schmitz BW, Innes GK, Prasek SM, Pogreba Brown KM, Stark
539 ER, et al. COVID-19 containment on a college campus via wastewater-based
540 epidemiology, targeted clinical testing and an intervention. Sci Total Environ.
541 2021;779:146408.

542 3. Corchis-Scott R, Geng Q, Seth R, Ray R, Beg M, Biswas N, et al. Averting an
543 Outbreak of SARS-CoV-2 in a University Residence Hall through Wastewater
544 Surveillance. Microbiol Spectr. 2021;9(2):e0079221.

545 4. Gibas C, Lambirth K, Mittal N, Juel MAI, Barua VB, Roppolo Brazell L, et al.
546 Implementing building-level SARS-CoV-2 wastewater surveillance on a university
547 campus. Sci Total Environ. 2021;782:146749.

548 5. Jarvie M, M., Reed M, Southwell B, Wright D, Nguyen T, Ngoc, Thi. RT-ddPCR
549 Wastewater Monitoring of COVID-19 Across the Eastern Upper Peninsula of Michigan.
550 SSRN2022.

551 6. Scott LC, Aubee A, Babahaji L, Vigil K, Tims S, Aw TG. Targeted wastewater 552 surveillance of SARS-CoV-2 on a university campus for COVID-19 outbreak detection 553 and mitigation. Environ Res. 2021;200:111374.

554 7. Wong TE, Thurston GM, Barlow N, Cahill ND, Carichino L, Maki K, et al.
555 Evaluating the sensitivity of SARS-CoV-2 infection rates on college campuses to
556 wastewater surveillance. Infect Dis Model. 2021;6:1144-58.

8. Rondeau NC, Rose OJ, Alt ER, Ariyan LA, Elikan AB, Everard JL, et al.
Building-Level Detection Threshold of SARS-CoV-2 in Wastewater. Microbiol Spectr.
2023:e0292922.

560 9. Chua FJD, Kim SY, Hill E, Cai JW, Lee WL, Gu X, et al. Co-incidence of BA.1
561 and BA.2 at the start of Singapore's Omicron wave revealed by Community and
562 University Campus wastewater surveillance. Sci Total Environ. 2023;875:162611.

563 10. Vo V, Tillett RL, Papp K, Chang CL, Harrington A, Moshi M, et al. Detection of
564 the Omicron BA.1 Variant of SARS-CoV-2 in Wastewater From a Las Vegas Tourist
565 Area. JAMA Netw Open. 2023;6(2):e230550.

566 11. Pico-Tomàs A, Mejías-Molina C, Zammit I, Rusiñol M, Bofill-Mas S, Borrego
567 CM, et al. Surveillance of SARS-CoV-2 in sewage from buildings housing residents with
568 different vulnerability levels. Sci Total Environ. 2023;872:162116.

569 12. Lehto KM, Länsivaara A, Hyder R, Luomala O, Lipponen A, Hokajärvi AM, et

al. Wastewater-based surveillance is an efficient monitoring tool for tracking influenza A

571 in the community. Water Res. 2024;257:121650.

572 13. Conway MJ, Kado S, Kooienga BK, Sarette JS, Kirby MH, Marten AD, et al.
573 SARS-CoV-2 wastewater monitoring in rural and small metropolitan communities in
574 Central Michigan. Sci Total Environ. 2023;894:165013.

575 14. Galloway SE, Paul P, MacCannell DR, Johansson MA, Brooks JT, MacNeil A, et
576 al. Emergence of SARS-CoV-2 B.1.1.7 Lineage - United States, December 29, 2020577 January 12, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(3):95-9.

578 15. Conway MJ, Yang H, Revord LA, Novay MP, Lee RJ, Ward AS, et al. Chronic
579 shedding of a SARS-CoV-2 Alpha variant in wastewater. BMC Genomics.
580 2024;25(1):59.

581 16. Checkmahomed L, Carbonneau J, Du Pont V, Riola NC, Perry JK, Li J, et al. In
582 Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to
583 Resistance. Antimicrob Agents Chemother. 2022;66(7):e0019822.

584 17. Cox RM, Wolf JD, Lieber CM, Sourimant J, Lin MJ, Babusis D, et al. Oral
585 prodrug of remdesivir parent GS-441524 is efficacious against SARS-CoV-2 in ferrets.
586 Nat Commun. 2021;12(1):6415.

587 18. Kemp SA, Collier DA, Datir RP, Ferreira I, Gayed S, Jahun A, et al. SARS-CoV588 2 evolution during treatment of chronic infection. Nature. 2021;592(7853):277-82.

589 19. Camargo CH, Gonçalves CR, Pagnoca E, Campos KR, Montanha JOM, Flores
590 MNP, et al. SARS-CoV-2 reinfection in a healthcare professional in inner Sao Paulo
591 during the first wave of COVID-19 in Brazil. Diagn Microbiol Infect Dis.
592 2021;101(4):115516.

Ahmadi AS, Zadheidar S, Sadeghi K, Nejati A, Salimi V, Hajiabdolbaghi M, et
al. SARS-CoV-2 intrahost evolution in immunocompromised patients in comparison with
immunocompetent populations after treatment. J Med Virol. 2023;95(6):e28877.

Sarkar R, Saha R, Mallick P, Sharma R, Kaur A, Dutta S, et al. Emergence of a
novel SARS-CoV-2 Pango lineage B.1.1.526 in West Bengal, India. J Infect Public
Health. 2022;15(1):42-50.

599 22. Shah A, Rehmat S, Aslam I, Suleman M, Batool F, Aziz A, et al. Comparative 600 mutational analysis of SARS-CoV-2 isolates from Pakistan and structural-functional 601 implications using computational modelling and simulation approaches. Comput Biol 602 Med. 2022;141:105170.

603 23. Abdullaev A, Abdurakhimov A, Mirakbarova Z, Ibragimova S, Tsoy V,
604 Nuriddinov S, et al. Genome sequence diversity of SARS-CoV-2 obtained from clinical
605 samples in Uzbekistan. PLoS One. 2022;17(6):e0270314.

Zhu M, Zeng Q, Saputro BIL, Chew SP, Chew I, Frendy H, et al. Tracking the
molecular evolution and transmission patterns of SARS-CoV-2 lineage B.1.466.2 in
Indonesia based on genomic surveillance data. Virol J. 2022;19(1):103.

Laskar R, Ali S. Mutational analysis and assessment of its impact on proteins of
SARS-CoV-2 genomes from India. Gene. 2021;778:145470.

611 26. De Marco C, Marascio N, Veneziano C, Biamonte F, Trecarichi EM, Santamaria
612 G, et al. Whole-genome analysis of SARS-CoV-2 in a 2020 infection cluster in a nursing
613 home of Southern Italy. Infect Genet Evol. 2022;99:105253.

614 27. Ramesh S, Govindarajulu M, Parise RS, Neel L, Shankar T, Patel S, et al.
615 Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and
616 Vaccine Efficacy. Vaccines (Basel). 2021;9(10).

617 28. Wilkinson SAJ, Richter A, Casey A, Osman H, Mirza JD, Stockton J, et al.
618 Recurrent SARS-CoV-2 mutations in immunodeficient patients. Virus Evol.
619 2022;8(2):veac050.

620 29. Ulinici M, Soñora M, Orsini E, Licastro D, Dal Monego S, Todiras M, et al.
621 Genome Sequences of SARS-CoV-2 Strains from the Republic of Moldova. Microbiol
622 Resour Announc. 2023;12(1):e0113222.

30. Rehman S, Mahmood T, Aziz E, Batool R. Identification of novel mutations in
SARS-COV-2 isolates from Turkey. Arch Virol. 2020;165(12):2937-44.

- Abou-Hamdan M, Hamze K, Abdel Sater A, Akl H, El-Zein N, Dandache I, et al.
 Variant analysis of the first Lebanese SARS-CoV-2 isolates. Genomics. 2021;113(1 Pt
 2):892-5.
- Bas JK, Sengupta A, Choudhury PP, Roy S. Characterizing genomic variants and
 mutations in SARS-CoV-2 proteins from Indian isolates. Gene Rep. 2021;25:101044.

630 33. Sassi MB, Ferjani S, Mkada I, Arbi M, Safer M, Elmoussi A, et al. Phylogenetic
631 and amino acid signature analysis of the SARS-CoV-2s lineages circulating in Tunisia.
632 Infect Genet Evol. 2022;102:105300.

- 633 34. Omotoso OE, Olugbami JO, Gbadegesin MA. Assessment of intercontinents
 634 mutation hotspots and conserved domains within SARS-CoV-2 genome. Infect Genet
 635 Evol. 2021;96:105097.
- 636 35. Bills C, Xie X, Shi PY. The multiple roles of nsp6 in the molecular pathogenesis
 637 of SARS-CoV-2. Antiviral Res. 2023;213:105590.
- 638 36. Sun X, Liu Y, Huang Z, Xu W, Hu W, Yi L, et al. SARS-CoV-2 non-structural
 639 protein 6 triggers NLRP3-dependent pyroptosis by targeting ATP6AP1. Cell Death
 640 Differ. 2022;29(6):1240-54.
- 641 37. Equestre M, Marcantonio C, Marascio N, Centofanti F, Martina A, Simeoni M, et
 642 al. Characterization of SARS-CoV-2 Variants in Military and Civilian Personnel of an
 643 Air Force Airport during Three Pandemic Waves in Italy. Microorganisms. 2023;11(11).
- 644 38. Fang S, Liu S, Shen J, Lu AZ, Wang AKY, Zhang Y, et al. Updated SARS-CoV-645 2 single nucleotide variants and mortality association. J Med Virol. 2021;93(12):6525-34.
- 646 39. Tierling S, Kattler K, Vogelgesang M, Pfuhl T, Lohse S, Lo Porto C, et al. Rapid
 647 Base-Specific Calling of SARS-CoV-2 Variants of Concern Using Combined RT-PCR
 648 Melting Curve Screening and SIRPH Technology. Open Forum Infect Dis.
 649 2021;8(8):ofab364.
- 40. Patro LPP, Sathyaseelan C, Uttamrao PP, Rathinavelan T. The evolving proteome
 of SARS-CoV-2 predominantly uses mutation combination strategy for survival. Comput
 Struct Biotechnol J. 2021;19:3864-75.
- 41. Azad GK, Khan PK. Variations in Orf3a protein of SARS-CoV-2 alter its
 structure and function. Biochem Biophys Rep. 2021;26:100933.
- Franceschi VB, Caldana GD, Perin C, Horn A, Peter C, Cybis GB, et al.
 Predominance of the SARS-CoV-2 Lineage P.1 and Its Sublineage P.1.2 in Patients from
 the Metropolitan Region of Porto Alegre, Southern Brazil in March 2021. Pathogens.
 2021;10(8).
- 43. Hossain A, Akter S, Rashid AA, Khair S, Alam A. Unique mutations in SARS-
- 660 CoV-2 Omicron subvariants' non-spike proteins: Potential impacts on viral pathogenesis 661 and host immune evasion. Microb Pathog. 2022;170:105699.

44. Tegally H, Moir M, Everatt J, Giovanetti M, Scheepers C, Wilkinson E, et al.
Emergence of SARS-CoV-2 Omicron lineages BA.4 and BA.5 in South Africa. Nat Med.
2022;28(9):1785-90.

- 665 45. Cruz CAK, Medina PMB. Temporal changes in the accessory protein mutations
 666 of SARS-CoV-2 variants and their predicted structural and functional effects. J Med
 667 Virol. 2022;94(11):5189-200.
- 46. Zárate S, Taboada B, Muñoz-Medina JE, Iša P, Sanchez-Flores A, Boukadida C,
 et al. The Alpha Variant (B.1.1.7) of SARS-CoV-2 Failed to Become Dominant in
 Mexico. Microbiol Spectr. 2022;10(2):e0224021.
- 47. Dimonte S, Babakir-Mina M, Hama-Soor T, Ali S. Genetic Variation and
 Evolution of the 2019 Novel Coronavirus. Public Health Genomics. 2021;24(1-2):54-66.
- 48. Mohammad T, Choudhury A, Habib I, Asrani P, Mathur Y, Umair M, et al.
 Genomic Variations in the Structural Proteins of SARS-CoV-2 and Their Deleterious
 Impact on Pathogenesis: A Comparative Genomics Approach. Front Cell Infect
 Microbiol. 2021;11:765039.
- 49. Timmers L, Peixoto JV, Ducati RG, Bachega JFR, de Mattos Pereira L, Caceres
 RA, et al. SARS-CoV-2 mutations in Brazil: from genomics to putative clinical
 conditions. Sci Rep. 2021;11(1):11998.
- 50. Williams DM, Hornsby HR, Shehata OM, Brown R, Gallis M, Meardon N, et al.
 Establishing SARS-CoV-2 membrane protein-specific antibodies as a valuable
 serological target via high-content microscopy. iScience. 2023;26(7):107056.
- 51. Jörrißen P, Schütz P, Weiand M, Vollenberg R, Schrempf IM, Ochs K, et al.
 Antibody Response to SARS-CoV-2 Membrane Protein in Patients of the Acute and
 Convalescent Phase of COVID-19. Front Immunol. 2021;12:679841.
- 52. Sullivan DJ, Franchini M, Joyner MJ, Casadevall A, Focosi D. Analysis of antiSARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and
 unvaccinated convalescent plasma sources. Nat Commun. 2022;13(1):6478.
- 53. Flood MT, D'Souza N, Rose JB, Aw TG. Methods Evaluation for Rapid
 Concentration and Quantification of SARS-CoV-2 in Raw Wastewater Using Droplet
 Digital and Quantitative RT-PCR. Food Environ Virol. 2021;13(3):303-15.
- 54. Lu X, Wang L, Sakthivel SK, Whitaker B, Murray J, Kamili S, et al. US CDC
 Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory
 Syndrome Coronavirus 2. Emerg Infect Dis. 2020;26(8):1654-65.
- 55. Lee HW, Lee HM, Yoon SR, Kim SH, Ha JH. Pretreatment with propidium
 monoazide/sodium lauroyl sarcosinate improves discrimination of infectious waterborne
 virus by RT-qPCR combined with magnetic separation. Environ Pollut. 2018;233:306-14.
- Karthikeyan S, Levy JI, De Hoff P, Humphrey G, Birmingham A, Jepsen K, et al.
 Wastewater sequencing reveals early cryptic SARS-CoV-2 variant transmission. Nature.
 2022;609(7925):101-8.
- 57. Wrobel AG, Benton DJ, Xu P, Roustan C, Martin SR, Rosenthal PB, et al. SARSCoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and
 furin-cleavage effects. Nat Struct Mol Biol. 2020;27(8):763-7.
- 704 58. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et
 705 al. UCSF Chimera--a visualization system for exploratory research and analysis. J
 706 Comput Chem. 2004;25(13):1605-12.
- 707





3'

7a

N































RCSB PDB: 7KJR



RCSB PDB: 8CTK

RCSB PDB: 7F60



N/A

N/A

Table 1. GT Molecular	Variant Calling
-----------------------	-----------------

Location code	Sample date	VOC (%) ^a	Lineage(s) (%) ^b
VM	10-26-21	Alpha (94.2)	Q.3 (94.2)
VM	11-9-21	Alpha (94.9)	Q.4 (94.7)
VM	9-12-22	Alpha (97.3)	Q.4 (96.9)
VM	3-13-23	Alpha (98.0)	Q.4 (65.5)
VM	4-24-23	Alpha (97.9)	Q.4 (89.7)
VM	5-1-23	Alpha (97.4)	Q.4 (97.1)

a, Relative abundance of variants of concern (VOC) as a percentage

b, Relative abundance of VOC lineages as a percentage

Table 2. Total Records of Non-Spike Mutations Identified in a Chronic SARS-CoV-2 Alpha Variant

MUTATION	SRA	GenBank	Unique Samples
NSP1:S17I	1	0	1
NSP2:G445C (G265C) ^a	6	20	21
NSP3:S944L (S126L)	60	148	111
NSP3:D1184E (D366E)	6	8	6
NSP3:A1306S (A488S)	0	0	0
NSP3:H1545Y (H727Y)	1	4	2
NSP3:K1795Q (K977Q)	2	11	8
NSP3:R2115I (R1297I)	13	1	13
NSP3:H2520N (H1702N)	0	0	0
NSP3:S2661F (S1843F)	19	23	25
NSP4:M2796I (M33I)	33	39	41
NSP4:V2943F (V180F)	1	2	1
NSP4:I2961F (I198F)	0	0	0
NSP4:D2980G (D217G)	11	10	11
3CLpro:R3353K (R90K)	0	0	0
3CLpro:K3499R (K236R)	1	4	4
NSP6:L3606F (L37F)	714	984	977
NSP6:F3750V (F184V)	2	6	6
RdRp:S4618N (S229N)	13	29	18
RdRp:T5301N (T912N)	0	0	0
NSP15:E6709K (E260K)	2	2	2
NSP15:F6712L (F263L)	6	8	8
NSP16:R7011N (R216N)	0	0	0
ORF3a:I35K	42	56	46
ORF3a:E102D	1	2	2
ORF3a:G172R	0	1	0
ORF3a:M260K	11	17	15
M:D3N	13	14	19
M:Q19H	0	0	0
ORF6:D61E	0	0	0
ORF7a:T120I	34	72	63
ORF7b:A43V	43	68	65
N:N8D	2	3	2
N:S37P	28	48	48
N:F235S	0	0	0

^{*a*} ORF1*ab* mutations outside of parentheses were determined from the first amino acid in nsp1. ORF1*ab* mutations inside of parentheses were determined from the first amino acid of each protein and were required for this analysis.